Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia.
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech 
		Latest Video
New Stories
- 
					
						The 'Dispatched' Week in Review Podcast - 31 OctoberOctober 31, 2025 - - Podcast
- 
					
						Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retiresOctober 31, 2025 - - Australian Biotech
- 
					
						Immuron provides update on U.S. clinical trials for Travelan and IMM-529October 31, 2025 - - Australian Biotech
- 
					
						Firebrick Pharma launches new Nasodine Throat Spray for international marketsOctober 31, 2025 - - Australian Biotech
- 
					
						Amplia Therapeutics begins trading on U.S. OTCQB Venture MarketOctober 31, 2025 - - Australian Biotech
- 
					
						DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facilityOctober 31, 2025 - - Latest News
- 
					
						The continued 'false framing' aims to make us feel guilty for wanting more on healthOctober 31, 2025 - - Latest News
